Nazartinib mesylate
Catalog No. A21741
Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min?1 on EGFR(L858R/790M) mutant, respectively.
Catalog Num | A21741 |
---|---|
M. Wt | 591.12 |
Formula | C27H35ClN6O5S |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 1508250-72-3 |
Synonyms | EGF816 (mesylate), EGF 816, EGF-816 |
SMILES | O=C(C1=CC(C)=NC=C1)NC2=NC3=CC=CC(Cl)=C3N2[C@H]4CN(C(/C=C/CN(C)C)=O)CCCC4.CS(=O)(O)=O |
Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min?1 on EGFR(L858R/790M) mutant, respectively.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 16.92 mL | 84.59 mL | 169.17 mL |
0.5 mM | 3.38 mL | 16.92 mL | 33.83 mL |
1 mM | 1.69 mL | 8.46 mL | 16.92 mL |
5 mM | 0.34 mL | 1.69 mL | 3.38 mL |
*The above data is based on the productmolecular weight 591.12. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.